BioCentury | May 13, 2019
Financial News

Philogen bypasses VCs, taps Italian syndicate for €62M to fuel late stage cancer programs

With €62 million ($69.6 million) in series A cash to carry its two late-stage candidates through clinical development, Philogen will soon have to decide whether to rely on additional deals to find commercialization partners, or...
BioCentury | Jan 29, 2015
Targets & Mechanisms

Personalized tumor vaccines

...high-affinity mutant epitopes on the proteins ALG8 - a glycosyltransferase - and LAMA4 - an extracellular matrix component...
BioCentury | Jan 5, 2015
Emerging Company Profile

Mimicking proteoglycans

Symic Biomedical Inc. is developing a library of synthetic mimics that function like natural proteoglycans but are easier to manufacture and aren't susceptible to enzymatic degradation, opening up previously untapped therapeutic space. Proteoglycans, which are...
BioCentury | Dec 11, 2014
Targets & Mechanisms

PIEZO de resistance

A pair of recently identified calcium channels- PIEZO1 and PIEZO2-control the response of cartilage to heavy loads and offer new targets for joint injury and osteoarthritis, according to findings from a team at Duke University...
BioCentury | May 22, 2014
Cover Story

Ob(nox)ious fibrosis

Although Esbriet pirfenidone, the only marketed drug for idiopathic pulmonary fibrosis, has shown a mortality benefit, the effects are modest and there remains room for improvement. New preclinical findings suggest that inhibiting NADPH oxidase 4...
BioCentury | Mar 6, 2014
Distillery Therapeutics

Indication: Neurology

...a bifunctional neurotrophin that activates TrkB and TrkC and a bacterial chondroitinase that degrades the extracellular matrix component...
BioCentury | Oct 17, 2013
Targets & Mechanisms

sFGFR for achondroplasia

Achondroplasia treatments include surgical procedures to increase bone length and human growth hormone injections to stimulate growth, but neither restores normal stature. Moreover, additional interventions are required to treat the secondary consequences of short-limb dwarfism...
BioCentury | Mar 21, 2013
Targets & Mechanisms

Understanding fibrosis

Researchers at The University of Alabama at Birmingham have identified idiopathic pulmonary fibrosis as a repurposing opportunity for fasudil, a Rho kinase inhibitor that Asahi Kasei Pharma Corp. markets as Eril to treat aneurysm. The...
BioCentury | Mar 15, 2010
Regulation

Creating a pathway in IPF

FDA generally dislikes pooled analyses of data - especially if the endpoint wasn't the primary endpoint and especially if one of the two trials being combined missed the primary endpoint. But InterMune Inc. last week convinced...
BioCentury | Jan 31, 2008
Distillery Therapeutics

This Week in Therapeutics

...miR-335 expression blocked metastatic cell invasion. miR-335 suppressed metastasis through targeting transcription factor SOX4 and extracellular matrix component...
Items per page:
1 - 10 of 10